<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To determine the role of allogeneic, autologous and syngeneic hemopoietic stem cell transplantation (SCTx) as a treatment for severe <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> (AID) we performed a literature search employing Medline, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Lit and abstract books for reports on transplants for <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">blood disorders</z:e> and a concomitant AID </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> reviews, case reports and abstracts available between June 1977 and September 2001 were used and attempts made to update them by e-mail by the corresponding authors </plain></SENT>
<SENT sid="2" pm="."><plain>Disease-free survival (DFS) after allogeneic SCTx for 23 patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> was 78% at 16 years and survival in unmaintained remission of concomitant AID was 64% at 13 years </plain></SENT>
<SENT sid="3" pm="."><plain>DFS after allogeneic SCTx for 24 patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> was 87% at 15 years and survival in unmaintained remission for concomitant AID was 70% at 11 years </plain></SENT>
<SENT sid="4" pm="."><plain>DFS after autologous SCTx for 24 patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> was 48% at 6 years and survival in unmaintained remission for concomitant AID was 29% at 3 years </plain></SENT>
<SENT sid="5" pm="."><plain>Among 30 patients given allogeneic SCTx 19 developed <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) and 11 did not </plain></SENT>
<SENT sid="6" pm="."><plain>Upon clinically justified discontinuation of <z:hpo ids='HP_0000001'>all</z:hpo> immunosuppressive therapy, 3/11 patients without GVHD relapsed with their concomitant AID (freedom of AID-relapse 69% at 9 years), whereas none of 19 patients with GVHD did so (log rank: P = 0.0135) </plain></SENT>
<SENT sid="7" pm="."><plain>Freedom of AID-relapse was superior after allo SCTx compared to autologous SCTx (89% at 18 years vs 38% at 5 years; log rank: P = 0.0002) </plain></SENT>
<SENT sid="8" pm="."><plain>Our data suggest that a graft-versus-<z:hpo ids='HP_0002960'>autoimmunity</z:hpo> effect after allogeneic hemopoietic SCTx mediates elimination of <z:hpo ids='HP_0002960'>autoimmunity</z:hpo> </plain></SENT>
</text></document>